Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial Document date: 2020_3_24
ID: 6g34qwer_30
Snippet: In this trial, the clearance of virus has been evaluated by negative-conversion rate and the time to negative. At day 7, the rate of virus nucleic acid negative conversion in control group was 27.3% (3/11), and reached to 54.4% (6/11) at day 14. While, the rate was 76.5% (13/17) in meplazumab group at day 7, and reached to 94.1% (16/17) at day 14, which were significantly higher than control group (p=0.019 and p=0.022, respectively). The analysis.....
Document: In this trial, the clearance of virus has been evaluated by negative-conversion rate and the time to negative. At day 7, the rate of virus nucleic acid negative conversion in control group was 27.3% (3/11), and reached to 54.4% (6/11) at day 14. While, the rate was 76.5% (13/17) in meplazumab group at day 7, and reached to 94.1% (16/17) at day 14, which were significantly higher than control group (p=0.019 and p=0.022, respectively). The analysis of time to virus negative indicated that meplazumab-treated patients converted to negative in a shorter period than patients in control group significantly (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.014, HR=0.37, 95%CI[0.155-0.833], figure 5 ). All these data indicate an obvious benefit of meplazumab treatment in the clearance of SARS-CoV-2.
Search related documents:
Co phrase search for related documents- control group and meplazumab treatment: 1, 2, 3, 4, 5, 6
- control group and negative conversion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and negative conversion rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- control group and negative time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and negative time negative conversion rate: 1
- control group and nucleic acid control group negative conversion: 1
- control group and SARS clearance: 1, 2, 3, 4, 5, 6, 7, 8
- control group and short period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- control group and time analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group negative conversion and negative conversion: 1
- control group negative conversion and negative time: 1
- control group negative conversion and nucleic acid control group negative conversion: 1
- control group patient and negative time: 1, 2, 3, 4
- control group patient and short period: 1
- control group patient and time analysis: 1, 2
- meplazumab group and negative time: 1, 2
- meplazumab treatment and negative time: 1, 2, 3
- negative conversion and nucleic acid control group negative conversion: 1
- negative conversion and SARS clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date